Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138478

Published: 2020

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-140711

Published: 2020

Journal Articles

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136258

Published: 2020

Journal Articles

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Luciano J. Costa, MD PhD, Simona Iacobelli, Marcelo C. Pasquini, MD, Riddhi Modi, PhD, Luisa Giaccone, Joan Bladé, MD PhD, Stefan Schonland, Andrea Evangelista, Jose A. Perez-Simon, MD PhD, Parameswaran Hari, MBBS, MD, Elizabeth E. Brown, PhD MPH, Sergio A Giralt, MD, Francesca Patriarca, Edward A. Stadtmauer, MD FACP, Laura Rosinol, MD PhD, Amrita Y. Krishnan, MD, Goesta Gahrton, MD PhD, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 259.

https://doi.org/10.1182/blood-2019-121367

Published: 2019

Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Blood (2019) 134 (Supplement_1): 5549.

https://doi.org/10.1182/blood-2019-122939

Published: 2019

Journal Articles

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Carlos Fernandez de Larrea, MD PhD, Ignacio Isola, MD, Esther Moga, Maria Teresa Cibeira, MD PhD, Ester Lozano, PhD, Juan I. Arostegui, Montserrat Elena, Natalia Tovar, MD PhD, Jordi Yague, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2018-99-117385

Published: 2018

Journal Articles

Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM)

Blood (2018) 132 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2018-99-111102

Published: 2018

Journal Articles

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Patricia Ferraz, MD, Arturo Pereira, MD PhD, María Suárez-Lledó, MD, Gonzalo Gutiérrez-García, MD, Francesc Fernández-Avilés, MD, Laura Rosinol, MD PhD, Teresa Solano, Noemí Llobet, Carla Ramos, Pedro Marín, MD, Alvaro Urbano-Ispizua, MD, Montserrat Rovira, MD, Carmen Martinez, MD PhD

Blood (2018) 132 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2018-99-112985

Published: 2018

Journal Articles

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Blood (2018) 132 (Supplement 1): 124.

https://doi.org/10.1182/blood-2018-99-112899

Published: 2018

Journal Articles

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 474.

https://doi.org/10.1182/blood-2018-99-115050

Published: 2018

Journal Articles

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Luis Gerardo Rodríguez-Lobato, MD PhD, Carlos Fernández De Larrea, MD PhD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Joan Bladé, MD PhD, Laura Rosinol, MD PhD

Blood (2018) 132 (Supplement 1): 5573.

https://doi.org/10.1182/blood-2018-99-112089

Published: 2018

Journal Articles

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 1943.

https://doi.org/10.1182/blood-2018-99-116604

Published: 2018

Journal Articles

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

Enrique M. Ocio, MD, Laura Rosinol, MD PhD, Marta Grande, Bachelor's degree, Ana Ruiz-Zorrilla, MD, Alonso Fernandez, PhD MSc, Carmen Montoto, MD

Blood (2018) 132 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2018-99-114430

Published: 2018

Journal Articles

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2018) 132 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2018-99-112656

Published: 2018

Journal Articles

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2018-99-112222

Published: 2018

Journal Articles

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Carlos Fernandez de Larrea, MD PhD, David Moreno, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Ignacio Isola, MD, Laura Magnano, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 1610.

https://doi.org/10.1182/blood-2018-99-115038

Published: 2018

Journal Articles

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2017) 130 (Supplement 1): 402.

https://doi.org/10.1182/blood.V130.Suppl_1.402.402

Published: 2017

Journal Articles

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Mª Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 4362.

https://doi.org/10.1182/blood.V130.Suppl_1.4362.4362

Published: 2017

NARROW

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM)

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only